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Proton beam therapy and localised prostate
cancer: current status and controversies
J A Efstathiou*,1, P J Gray1 and A L Zietman1
1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Proton therapy is a promising, but costly, treatment for prostate cancer. Theoretical physical advantages exist; yet to date, it has
been shown only to be comparably safe and effective when compared with the alternatives and not necessarily superior. If
clinically meaningful benefits do exist for patients, more rigorous study will be needed to detect them and society will require this
to justify the investment of time and money. New technical advances in proton beam delivery coupled with shortened overall
treatment times and declining device costs have the potential to make this a more cost-effective therapy in the years ahead.
Proton beam is a form of externally delivered radiation that has
been in therapeutic use for over 40 years. The beam has certain
unique physical attributes that make it particularly attractive for
the treatment of cancer (Wilson, 1946). In particular the stream of
positively charged subatomic particles enters tissue and deposits
the bulk of its energy in the last few millimetres of the beam range.
Tissue beyond this point receives very little radiation dose because
of the absence of exit dose (Figure 1). It is upon this premise that
the enthusiasm for proton beam therapy (PBT) has been built.
The concept that tumours can be targeted with very little radiation
being delivered to the adjacent normal tissues is particularly
appealing, especially, when considering exquisitely sensitive
normal tissues such as the brain stem, eye, spinal cord, or any
tissue in a developing child. The promise of lowering morbidity
and the risk of second radiation-induced cancers while, at the same
time, escalating the cancer dose to more reliably eradicate the
tumour has garnered justifiable enthusiasm.
Over the last two decades, PBT has developed much support for
the treatment of paediatric cancers, and cancers of the eye, skull
base, and spine. The early evidence of benefit was theoretical and
came from simple demonstrations that normal tissues receive less
radiation dose. The outcome benefits have, until recently,
been presumed. New patient outcome data are emerging, showing,
for example, a lower incidence of vision or hearing loss and
improved neurocognitive function in paediatric cancers
(MacDonald et al, 2008; Childs et al, 2012) and a lower incidence
of second malignancies in paediatric cases overall (Miralbell et al,
2002; Chung et al, 2008).
Skull base and paediatric tumours are, however, rare, and when
one considers the current cost for building a full 3–4 treat-
ment room PBT cyclotron facility in the United States, up to
$150–200 million, the question becomes is it worth the cost
in an economic sense? (Pollack, 2007; Emanuel, 2012). For this
reason, the manufacturers of proton beam equipment and several
centres that have installed them may be looking at the more
common cancers as a means of supporting the facilities. Prostate
cancer has been a particular focus of attention and any patient who
‘Googles’ the term will rapidly arrive at proton beam as a highly
advocated option (Shah et al, 2012a) leading to ‘proton-seeking’
behaviour. The hope exists that use of this technology will reduce
the well-documented morbidity of prostate cancer treatment but
outcome data studying its use has, until recently, been relatively
thin. In the United States, prostate cancer has become one of the
economic drivers for the establishment of new proton beam
facilities, and this is the area where use of this technology is being
most closely scrutinised by physicians and policy makers alike. It is
on this area of controversy that our discussion will focus.
THE PHYSICAL UNCERTAINTIES
The physics of radiation therapy with a beam of proton particles
has been well established, and attractive radiation dose-distribution
maps can be generated that show highly conformal treatment
delivery (Figure 2). Uncertainties do, however, exist and some of
these pertain to the treatment of deep-seated tumours such as the
prostate (Goitein, 2008). Although the beam can be stopped in
tissue sharply over the first 10 cm, at greater depths such as the
depth of the average prostate gland, there is ‘end-of-range
uncertainty’, and a penumbra develops laterally and around the
distal end of the beam. This can blur the beam’s sharp edge,
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delivering higher doses of radiation than anticipated to adjacent
normal tissues. In addition, a proton beam is sensitive to tissue
density and heterogeneity and may be perturbed by passage
through very inhomogeneous tissue, such as bone, and then muscle
of the pelvis. This becomes more of an issue if the bone is not fully
immobilised as can be the case with the hips due to anatomical
variation in femur angle (Trofimov et al, 2011). Similarly, targeting
of dose can be affected significantly when organs move over the
course of therapy (Wang et al, 2011). Protons may be associated
with less scatter dose the further you get away from the prostate
(Yoon et al, 2010) and consequently some modelling studies have
reported lower rates of radiation-associated second cancers both
in-field and out-of-field (Fontenot et al., 2009). However, neutrons
may be produced and scattered from the heads of some types of
proton treatment machines. The high radiobiological effect of
neutrons has the risk of causing more secondary cancers than more
conventional radiation treatment, thus potentially negating one of
the putative advantages of the therapy (Brenner and Hall, 2008;
Athar et al, 2010). Although efforts are underway to address some
of the limitations associated with delivery of protons (Brenner et al,
2009; Tang et al, 2012), these physical uncertainties continue to
generate much heated debate in the radiation oncology literature
and are yet to be fully settled.
THE CLINICAL EVIDENCE
The management of localised prostate cancer has been a subject of
debate for over 30 years. Surgery has improved in quality and
proliferated in technique (open, laparoscopic, robotic assisted, and
focal). Radiation therapy has done exactly the same (conventional
2-D, conformal 3-D, intensity-modulated radiation therapy
(IMRT), stereotactic, and high- and low-dose brachytherapy).
The majority of the radiation treatments for prostate cancer
delivered in the United States today are given either by IMRT, a
method that uses inhomogeneous photon beams of non-uniform
intensity to sculpt around critical structures like the rectum, or
brachytherapy, a procedure that involves the implantation of
radioactive devices directly into the prostate. In addition, elegant
modes of daily immobilisation and localisation of the prostate
using image-guided radiation therapy techniques have been
generally adopted. Of note, at this stage, modes of image guidance
(i.e., daily cone beam computed tomography or electromagnetic
emitting transponders) are generally more advanced (and in fact
more costly) for IMRT than proton beam. Although many studies
have documented either increased rates of cancer eradication or
better patient quality of life with modern techniques delivering
contemporary high doses of radiation (Zelefsky et al, 2001; Sanda
et al, 2008; Zietman et al, 2010a; Bekelman et al, 2011; Michalski
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Figure 2. (A) With intensity-modulated radiation therapy (IMRT),
between 5 and 9 inhomogeneous X-ray beams from different angles
are used to conform the high radiation dose to the prostate. With 3-D
conformal proton therapy (3DCPT), the dose is delivered with two
lateral scattered beams shaped by apertures to create a uniform field.
With intensity-modulated proton therapy (IMPT), dose is delivered by
scanning a narrow pencil beam across the target in three dimensions,
and modulating both the current and energy of the beam to yield dose
distributions that are typically more conformal to the target than with
3DCPT. (B) When subtracting dose between proton and IMRT plans,
one is left with an excess low-dose radiation bath over a larger region of
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Figure 1. Radiation dose delivered at a certain depth in the body for a
X-ray photon beam (red), the Bragg peak of an individual proton beam
(dashed blue), and a spread-out Bragg peak combining multiple
proton beams to cover the target (solid blue). The excess X-ray dose at
entrance and at exit is highlighted.
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there has been sparse high-quality evidence supporting one
technology over another. Although, one randomised comparison
did demonstrate a benefit to 2-D vs 3-D (Dearnaley et al, 1999),
in general, there has been rapid and uncontrolled marketing,
demand, dissemination, and implementation of new and promis-
ing technologies (both hardware and software) before their
effectiveness and comparative value have been rigorously
evaluated. The increased need for cost-control inevitably will
demand higher levels of evidence supporting clinical efficacy and
cost-effectiveness. The question remains whether or not proton
beam with its current high price tag brings added value.
Only one randomised trial exists comparing conventional
radiation therapy with proton beam, and this was initiated in the
1980s using older techniques and treating advanced disease in the
era before early detection with PSA (Shipley et al, 1995). There was
no difference in outcome between the two arms, but this study is
now of historical interest only. Several studies comparing the
dosimetry of proton beam with IMRT have been published and,
depending upon the choice of beams and planning systems, IMRT
can be seen as theoretically a little better or a little worse than
protons (Trofimov et al, 2007; Vargas et al, 2008; Nihei et al, 2011).
Our own work suggests that the conformity of dose distribution to
the prostate may be better with IMRT. In the high-dose regions,
IMRT shows better sparing of the bladder and rectal sparing is
similar, whereas in the low-dose regions, proton beam achieves
better sparing of both rectum and bladder (Trofimov et al, 2007).
Thus, IMRT creates more of a low-dose radiation ‘bath’ over a
larger region of the pelvis and leads to a higher, though still
relatively small, whole-body radiation dose (Figure 2). This begs
the question whether the worse morbidity of radiation therapy
comes from the high-dose area (sexual, rectal, and bladder
functions) or the cumulative low-dose areas (fatigue, bowel
function, and second cancers). Dosimetric studies showing
relatively modest differences in physical dose distribution are of
little value without looking for measurable and meaningful
differences in clinical outcome. Although radiation oncologists
have been eager to adopt proton beam for prostate cancer, they
have been slow to perform clinical studies. This is now being
addressed. Recent prospective clinical studies have documented
certain truths about proton beam and prostate cancer.
First, that radiation dose escalation to the prostate may be safely
achieved. We have shown that patient-reported quality of life is the
same at doses of either 70 or 79Gy when the boost dose is
delivered by protons (Talcott et al, 2010). This does not, however,
address the fact that escalation to the same doses may be achieved
and be equally well tolerated by other radiation techniques like
IMRT or brachytherapy. That is to say that, despite the theoretical
physical advantages of proton therapy, studies have yet to show
any clear clinical benefit to proton beam over IMRT in terms of
morbidity in the treatment of prostate cancer. No direct head-to-
head comparison between the two has yet been done, although a
multicenter randomised trial has recently been launched (discussed
below). Talcott et al (2010) did make comparisons between two
separate, though contemporary, cohorts of patients treated with
proton beam or either IMRT or 3-D conformal therapy and found
no overt differences. The principal concerns of patients, erectile
dysfunction, voiding dysfunction, and rectal dysfunction, appear to
occur with similar acceptably low frequency. We have generated
some preliminary data suggesting transient differences in toxicity
patterns with a potential early short-term, though time-limited,
improvement in bowel and urinary symptoms with PBT vs IMRT
(Gray et al, 2013). New data from other US proton centers are also
demonstrating excellent quality of life outcomes and low rates of
significant early gastrointestinal and genitourinary toxicity, with
proton-based therapy for prostate cancer, although these may
come from the use of prostate immobilisation and image guidance
as much as from the use of proton beam (Mendenhall et al, 2012).
Two other recent studies, however, have suggested that PBT is
associated with increased bowel toxicity compared with IMRT
(Kim et al, 2011; Sheets et al, 2012). These studies rely on billing
codes that may not capture the patient’s own experience and large
databases that contain few PBT patients and also lack data on
treatment dose, margins, and other important relevant clinical
factors. As such, the validity of these conclusions remains a matter
of debate. It is also worth noting that the follow-up from all of
these studies is too short to capture all the late effects of radiation,
which may continue to accumulate at 10 years or beyond (Gardner
et al, 2002).
Second, that cancer-control rates after proton beam are as good
as those obtained with any other kind of radiation therapy
(Zietman et al, 2010a). Proton beam is certainly an effective
addition to the armamentarium. Although there are no completed
randomised trials, there is one recent case-matched comparison
that shows identical cancer-control rates between proton beam and
brachytherapy (Coen et al, 2012). Given that there is no evidence
that proton beam is superior to other therapies in terms of prostate
cancer control, it might be an improved (and more costly) means
to an unimproved end.
Third, that using current proton delivery methods (passively
scattered beams), radiation dose cannot be escalated significantly
higher to achieve better cancer-control rates. A prospective study
performed at the MGH and Loma Linda Medical Centre concluded
that morbidity reaches the limits of acceptability at 82Gy, with
rectal bleeding becoming a dose-limiting toxicity (Coen et al, 2011).
COST AND USAGE
Although these data supporting the efficacy of PBT continue to
emerge, much attention has also focused on the cost of PBT
relative to existing technologies. The number of centres offering
proton therapy in the United States is expected to double in the
next 3 years (Johnson, 2012), and prostate cancer patients may
represent up to 75% of the future consumers at these centres
(Jarosek et al, 2011). An analysis using Markov models informed
by cost and efficacy data was conducted to compare the cost-
effectiveness of 91.8 Gy (RBE) delivered with proton beam to 81Gy
delivered with IMRT. It was assumed that this 10Gy dose
escalation would result in a survival advantage without an increase
in toxicity, though this remains debatable as previously discussed
(Coen et al, 2011). Despite this assumption, the incremental cost-
effectiveness ratio for PBT was calculated to be $63 578 per QALY
for a 70-year-old man and $55 726 per QALY for a 60-year-old
man. Using the commonly accepted standard of $50 000 per
quality-adjusted life year, PBT did not appear to be cost-effective
(Konski et al, 2007). Other economic reviews have found the
lifetime cost for treatment, follow-up, and management of
recurrence and side effects to be $53 828 for PBT, $37 861 for
IMRT, $25 484 for brachytherapy, $28 348 for radical prostatect-
omy, and $30 422 for active surveillance (Ollendorf et al, 2009).
The exact degree of the incremental increase in cost for PBT over
IMRT remains a subject of debate, however. One recent study
suggested the median amount reimbursed by the US Medicare
insurance program was $32 428 for PBT and $18 575 for IMRT
(Yu et al, 2013). There are clear ranges of costs that are billed and
reimbursed depending on provider and payer, and ways in which
cost is modelled, highlighting that pricing considerations remain a
moving target, and these will adapt and be fluid in the era of
health-care payment reform.
Two future trends may, however, reduce the cost of proton
beam delivery and make it a more competitive option for patients.
First, several randomised and other trials (Kupelian et al, 2007;
Boike et al, 2011; Arcangeli et al, 2012; Dearnaley et al, 2012) have
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published early results suggesting safety and equivalence between
conventional fractionation and hypo-fractionation (i.e., shorter
treatment regimens that deliver fewer larger fractions of radiation
that may offer a therapeutic gain) in prostate cancer, and proton
beam is being investigated in this manner (Radiation Therapy
Oncology Group protocol 0938). As the cost of treatment delivery
in the United States is proportional to the number of fractions
given, this alone may not only lead to cost savings but also better
resource allocation and increased patient convenience. Indeed,
decreasing the total number of fractions delivered from 44 to 28 or
as few as 5, could result in a significant reduction in the incremental
cost difference of PBT. The second is that there is a natural trend
towards simplification and streamlining of any technology as it
matures. New single gantry facilities are being developed with a
$15–25 million price tag. Although this still remains costlier than
most other medical technologies (for example a linear accelerator
capable of delivering IMRT may cost $1-5 million), the debt
incurred may be managed without requiring such high patient
throughput and high treatment charges. As further technical
advances and operational efficiencies are employed, further
lowering of the cost gap between proton- and photon-based
techniques will likely occur.
THE FUTURE
Proton beam therapy has not yet reached its full potential. The use
of spot-scanned delivery is being adopted, and this technique allows
for greater intensity modulation (Figure 2). Together with the use of
more creative beam angles, conformality should be taken to new
heights (Trofimov et al, 2007; Tang et al, 2012). It remains
debatable, however, whether or not this will translate into fewer side
effects and/or allow the delivery of higher doses to the prostate as
most of the morbidity comes from irradiation of the prostatic
urethra, bladder neck, anterior rectum, and nerves. These tissues are
either within the prostate or immediately adjacent to it and are
unlikely to be significantly further spared without undertreating the
prostate itself. Focal or partial prostate therapy is being examined
for very early cancers using focused ultrasound or cryotherapy, and
it is possible that intensity-modulated protons could have a similar
role. Alternatively, protons could be used to deliver partial prostate
boosts in the case of more advanced cancer (Figure 3).
If PBT were exactly the same cost as other forms of external
radiation, there may be less of a discussion. It would simply be
regarded as another arrow in the quiver of radiation options with
potential theoretical benefits. It is, however, the powerful advocacy
for its superiority ahead of rigorous evidence that attracts
suspicion. In this way, PBT is illustrative of a broad problem in
medicine generally. How can promising new and emerging
technologies that are rapidly evolving be evaluated in a rigorous
and sufficiently timely fashion such that creativity and innovation
are not stifled? The vast majority of new technologies are
incremental advances of existing techniques that do not require
testing beyond that of basic safety as mandated by governmental
regulatory bodies. Alternative methodologies such as prospective
observational registries (as has been done for PET scanning
and cardiac devices) may be employed to assess efficacy and
appropriate utilisation. For a few technologies, however, and
proton beam is arguably one of them, there has not been a simple
incremental evolution but a gigantic revolution. It is here that
randomised controlled trials (RCTs) may still have a role, and the
earlier they are initiated the better (Zietman et al, 2010b). It has
been argued that the RCT remains crucial when: the new
technology introduces a new biology; when retraining or re-
credentialing is required; when the technology is as likely to be less
effective as it is more effective than the alternatives; or when the
technology carries such a price that it will alter the resources
available to care for others. Proton beam meets several of these
criteria. The relative radiobiological effectiveness is not known with
absolute accuracy for different tissues, and this may matter when
ultra-high doses are being delivered (Carabe-Fernandez et al,
2011). For this reason, and because of the differences in dose
distribution between protons and IMRT, there are circumstances
where the outcome may be worse and not necessarily better.
A RCT is, however, not necessary for every disease or every site
to be treated by protons. It is clear, for example, that there will be
little advantage to treating superficial skin cancers this way.
Equally, there would be few willing to randomise paediatric
patients because the theoretical advantages of proton beam are so
great and the consequences of more conventional treatment so
devastating that therapeutic equipoise, a central requirement of any
RCT, could not be assumed (Hellman and Hellman, 1991).
Furthermore, a RCT would be impractical for rare indications
(such as skull base chordomas) or when patients are unwilling to
be randomised (van Loon et al, 2012). As such, RCTs should be
reserved for the ‘grey zones’, such as prostate cancer, where we
need to document not only efficacy and safety (done already) but
to quantitate value added. Patients have indicated their willingness
to participate in such a trial for prostate cancer (Shah et al, 2012b).
Several major US proton centers led by the Massachusetts General
Hospital and University of Pennsylvania have recently launched a
phase III randomised trial of IMRT vs PBT for localised low and
low-intermediate risk prostate cancer (http://clinicaltrials.gov/ct2/
show/NCT01617161), with patient-reported quality of life out-
comes, as well as other clinical, physical, biological, and economic
end points (including assessing cost-effectiveness under current
and future conditions for alternative treatment delivery and pricing
scenarios). Events are moving too fast, and the answers this trial
will provide cannot come too soon.
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Figure 3. Use of diagnostic imaging, image guidance, and sharper
beams with intensity-modulated proton therapy (IMPT) to deliver non-
uniform focal boost doses (i.e., 480Gy) to part of the prostate
(purple-colour wash).
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